Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability

Fatty acid binding protein 5 (FABP5), an intracellular lipid binding protein, has been shown to play a role in various cancers, including breast cancer. However, FABP5 and its role in triple negative breast cancer (TNBC) have not been studied. We show FABP5 protein expression correlates with TNBC, high grade tumors, and worse disease-free survival in a tissue microarray containing 423 breast cancer patient samples. High FABP5 expression significantly correlates with epidermal growth factor receptor (EGFR) expression in these samples. Decreased tumor growth and lung metastasis were observed in FABP5−/− mice othotopically injected with murine breast cancer cells. FABP5 loss in TNBC tumor cells inhibited motility and invasion. Mechanistic studies revealed that FABP5 knockdown in TNBC cells results in decreased EGFR expression and FABP5 is important for EGF-induced metastatic signaling. Loss of FABP5 leads to proteasomal targeting of EGFR. Our studies show that FABP5 has a role in both host and tumor cell during breast cancer progression. These findings suggest that FABP5 mediates its enhanced effect on TNBC metastasis, in part, through EGFR, by inhibiting EGFR proteasomal degradation. These studies show, for the first time, a correlation between FABP5 and EGFR in enhancing TNBC metastasis through a novel mechanism.

[1]  H. Leffers,et al.  Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. , 1992, The Journal of investigative dermatology.

[2]  T. Ono,et al.  Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer. , 2000, Cancer research.

[3]  P. Rudland,et al.  Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. , 2001, Cancer research.

[4]  R. Parker,et al.  Role of the fatty acid binding protein mal1 in obesity and insulin resistance. , 2003, Diabetes.

[5]  C. Shi,et al.  Pyk2 Amplifies Epidermal Growth Factor and c-Src-induced Stat3 Activation* , 2004, Journal of Biological Chemistry.

[6]  M. J. Ehrke,et al.  Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. , 2005, Anticancer research.

[7]  L. Makowski,et al.  The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis , 2005, Current opinion in lipidology.

[8]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[9]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[10]  Erik Sahai,et al.  Illuminating the metastatic process , 2007, Nature Reviews Cancer.

[11]  W. Travis,et al.  Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis. , 2007, Archives of pathology & laboratory medicine.

[12]  M. Furuhashi,et al.  Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. , 2008, The Journal of clinical investigation.

[13]  M. Furuhashi,et al.  Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets , 2008, Nature Reviews Drug Discovery.

[14]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[15]  G. Tuszynski,et al.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis , 2009, Pathology Oncology Research.

[16]  M. Clynes,et al.  Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Suttles,et al.  Regulation of Th17 Differentiation by Epidermal Fatty Acid-Binding Protein1 , 2009, The Journal of Immunology.

[18]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[19]  C. Lipinski,et al.  Targeting Pyk2 for therapeutic intervention , 2010, Expert opinion on therapeutic targets.

[20]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[21]  C. Morrison,et al.  Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features , 2011, Breast Cancer Research and Treatment.

[22]  W. Chiang,et al.  Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[23]  Padmamalini Kannan-Thulasiraman,et al.  Involvement of Fatty Acid Binding Protein 5 and PPARβ/δ in Prostate Cancer Cell Growth , 2010, PPAR research.

[24]  Stephanie Alexander,et al.  Cancer Invasion and the Microenvironment: Plasticity and Reciprocity , 2011, Cell.

[25]  Padmamalini Kannan-Thulasiraman,et al.  Fatty acid-binding protein 5 and PPARβ/δ are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. , 2011, The Journal of Biological Chemistry.

[26]  J. Mackey,et al.  Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. , 2011, The American journal of pathology.

[27]  Tao Qin,et al.  EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray , 2012, Medical Oncology.

[28]  M. Linton,et al.  Macrophage Mal1 Deficiency Suppresses Atherosclerosis in Low-Density Lipoprotein Receptor–Null Mice by Activating Peroxisome Proliferator-Activated Receptor-&ggr;–Regulated Genes , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[29]  S. Borstnar,et al.  Triple negative breast cancer – prognostic factors and survival , 2010, Radiology and oncology.

[30]  E. Rakha,et al.  Metastatic triple-negative breast cancer. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[31]  K. Gelmon,et al.  Targeting triple-negative breast cancer: optimising therapeutic outcomes. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  R. Okuyama,et al.  Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. , 2012, Journal of dermatological science.

[33]  Hiroko Masuda,et al.  Role of epidermal growth factor receptor in breast cancer , 2012, Breast Cancer Research and Treatment.

[34]  K. Shilo,et al.  S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. , 2011, Cancer research.

[35]  Gregory P Tochtrop,et al.  Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. , 2013, Cancer research.

[36]  K. Imai,et al.  Comprehensive fluorogenic derivatization-liquid chromatography/tandem mass spectrometry proteomic analysis of colorectal cancer cell to identify biomarker candidate. , 2013, Biomedical chromatography : BMC.

[37]  R. Greil,et al.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Shilo,et al.  FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway , 2014, Oncotarget.

[39]  J. Iovanna,et al.  Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations , 2014, British Journal of Cancer.

[40]  B. Yadav,et al.  Systemic treatment strategies for triple-negative breast cancer. , 2014, World journal of clinical oncology.